Repligen Corporation to Present at Upcoming November Conferences - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming investor conferences.
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
Repligen ( RGEN ) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +9.52% and +4.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. ( APLS ) Reports Next Week: Wall Street Expects Earnings Growth
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALKS vs. RGEN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Alkermes ( ALKS Quick QuoteALKS - ) or Repligen ( RGEN Quick QuoteRGEN - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Earnings Preview: Repligen ( RGEN ) Q3 Earnings Expected to Decline
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen to Report Third Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET ...
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - FactSet Research Systems ( NYSE:FDS ) , Brinker International ( NYSE:EAT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Eddie Kim upgraded Helmerich & Payne, Inc.
Repligen Corporation to Present at Upcoming September Conferences - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences. The Wells Fargo Healthcare Conference, being held September 3 - ...
Repligen Corporation to Present at Upcoming September Conferences
WALTHAM, Mass., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.
Do Options Traders Know Something About Repligen Stock We Don't?
Investors need to pay close attention to RGEN stock based on the movements in the options market lately.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 - Repligen ( NASDAQ:RGEN )
Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue. Here's a breakdown of the stock's current structure. According to Adhishthana principles, a stock typically breaks out of its Cakra pattern in Phase 9, which starts ...
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign's machine learning and modeling ...
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
WALTHAM, Mass., July 29, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2025, covering the three- and six- month periods ended June 30, 2025.
Here's Why Repligen ( RGEN ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Repligen to Report Second Quarter 2025 Financial Results - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., July 17, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 ...
Repligen to Report Second Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET ...
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Gold Royalty ( AMEX:GROY ) , IonQ ( NYSE:IONQ )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday. Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure ...
Do Options Traders Know Something About Repligen ( RGEN ) Stock We Don't?
Investors need to pay close attention to Repligen (RGEN) stock based on the movements in the options market lately.
Why Is Repligen ( RGEN ) Down 12.2% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., May 27, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures.
Repligen Corporation to Present at William Blair Growth Conference - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., May 22, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 - 5 in Chicago.
Repligen Corporation to Present at Upcoming May Investor Conferences - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., May 07, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
QGEN or RGEN: Which Is the Better Value Stock Right Now?
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Repligen ( RGEN ) Tops Q1 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 11.43% and 2.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Repligen Reports First Quarter 2025 Financial Results
WALTHAM, Mass., April 29, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025.
Will Repligen ( RGEN ) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Guardant Health ( GH ) Q1 Earnings Expected to Decline
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen ( RGEN ) Reports Next Week: Wall Street Expects Earnings Growth
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GMAB or RGEN: Which Is the Better Value Stock Right Now?
GMAB vs. RGEN: Which Stock Is the Better Value Option?
Repligen to Report First Quarter 2025 Financial Results - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., April 15, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 ...
Repligen to Report First Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ET ...
Repligen Appoints Jacob Johnson As Vice President Investor Relations - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., April 08, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the ...
Repligen ( RGEN ) Moves 3.7% Higher: Will This Strength Last?
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis Pharma ( ASND ) Soars 10.4%: Is Further Upside Left in the Stock?
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - 908 Devices ( NASDAQ:MASS ) , Repligen ( NASDAQ:RGEN )
908 Devices sold its desktop portfolio to Repligen for $70 million, reducing $20 million in annual operating losses. 908 Devices expects 2025 revenue of $53 million-$55 million, with EBITDA positivity by Q4 2025. Every week, our Whisper Index uncovers five overlooked stocks with big breakout ...
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Portfolio includes PAT devices for real-time process monitoring, control and analysis Portfolio includes PAT devices for real-time process monitoring, control and analysis ...
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - 908 Devices ( NASDAQ:MASS ) , Repligen ( NASDAQ:RGEN )
WALTHAM, Mass. and BOSTON, March 04, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN, a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc.
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook - Repligen ( NASDAQ:RGEN )
Repligen Q4 EPS of $0.44 beat the $0.41 estimate, while revenue of $167.55 million was in line with forecasts. 2025 sales guidance set at $685 million-$710 million vs. $694.9 million consensus, with organic growth of 9.5%-13.5%.
Repligen's Q4 Slightly Tops Expectations
The bioprocessing technology specialist's fourth-quarter results were dragged down by restructuring costs.
Repligen ( RGEN ) Beats Q4 Earnings Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 7.32% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2024, covering the three- and twelve-month periods ended December 31, 2024.
Axsome Therapeutics ( AXSM ) Reports Q4 Loss, Tops Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of 4% and 0.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company will issue a press release before the market opens and will host a conference call at ...
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET ...
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. ( HRMY Quick QuoteHRMY - ) and Repligen ( RGEN Quick QuoteRGEN - ) . But which of these two stocks presents investors with the better value opportunity right now?
Repligen ( RGEN ) Surges 3.7%: Is This an Indication of Further Gains?
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
